Questionnaire to identify influenza vaccine, diagnostic and pharmaceutical manufacturers using WHO Global Influenza Surveillance and Response System (GISRS) under Section 6.14.3 of the PIP Framework

Purpose and background

The purpose of this questionnaire is to determine if your company/institution falls into a category of "Influenza vaccine, diagnostic and pharmaceutical manufacturers using the Global Influenza Surveillance and Response (GISRS)." Your national government, along with 193 other countries, agreed to establish this category as part of the Pandemic Influenza Preparedness Framework (the "PIP Framework"), a 2011 internationally-agreed policy on global public health.

The PIP Framework brings together many stakeholders, including industry, that are to work together to ensure that the world is better prepared to respond to the next pandemic influenza. A specific element of the PIP Framework is an annual "Partnership Contribution" that is to be made to WHO by "Influenza vaccine, diagnostic and pharmaceutical manufacturers using the WHO Global Influenza Surveillance and Response System (GISRS)" (see Framework Section 6.14.3). The Framework defines "influenza vaccine, diagnostic and pharmaceutical manufacturers" as follows: "Influenza vaccine, diagnostic and pharmaceutical manufacturers" means public or private entities including academic institutions, government owned or government subsidized entities, nonprofit organization or commercial entities that develop and/or produce human influenza vaccines or other products derived from or using H5N1 or other influenza viruses of human pandemic potential" (see Framework section 4.3).

To be identified as a contributor to the annual Partnership Contribution, an entity must be a manufacturer and use GISRS. Entities that are manufacturers under the PIP Framework but do not "use GISRS" are not expected to make a Partnership Contribution. Entities that "use GISRS" but are not manufacturers are not expected to make an annual Partnership Contribution. This questionnaire explains what is understood by the terms "manufacture" and "use GISRS".

The Secretariat will publish the results of this questionnaire on the WHO PIP Framework internet page. This will include: list of companies contacted; responses provided; and list of companies that did not respond.

Responses must be received no later than 31 October 2012.

Fields marked with an asterisk (*) are mandatory.

Contact details

Company name *

Address *

Country *

Name and title of contact person *
Do you develop human influenza vaccines or other products derived from or using H5N1 or other influenza viruses of human pandemic potential?

In the question above, “develop” is understood to mean that you have developed a product (including human influenza vaccine, antiviral, diagnostic or other product) that can be used to treat or diagnose infections from H5N1 or other influenza viruses with human pandemic potential, and you have obtained a provisional or final licensure, registration or market authorization for such product, but have not implemented production, distribution or sales.

Please answer *  

Yes  No

Do you produce a human influenza vaccine or other product derived from or using H5N1 or other influenza viruses of human pandemic potential?

In the question above, “produce” is understood to mean that you produce a product (including human influenza vaccine, antiviral, diagnostic or other product) that can be used to treat or diagnose infections from H5N1 or other influenza viruses with human pandemic potential, and such product has obtained national licensure, registration or market authorization, and you have implemented production, distribution or sales of this product. This would include, for example, producing vaccine from procured bulk material.

** As this term is defined by most National Regulatory Authorities for medicinal products.

Please answer *  

Yes  No

Do you use GISRS?

In the question above, “use GISRS” is understood to mean that in your product development, testing, production or marketing you have used or received information not routinely provided to the general public (such as analysis of viruses, viral sensitivity or epidemiological analyses), materials or services from GISRS.

Please answer *  

Yes  No